
Strongbridge Biopharma plc Retained Earnings 2011-2026 | SBBP
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Strongbridge Biopharma plc
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -306 M | -260 M | -211 M | -243 M | -129 M | -80.8 M | -37.2 M | -27.6 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.6 M | -306 M | -162 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.8 | 5.33 % | $ 9.14 B | ||
|
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
-334 M | $ 2.63 | -1.22 % | $ 16.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
-410 M | $ 88.34 | -3.22 % | $ 27.2 B | ||
|
Akari Therapeutics, Plc
AKTX
|
-265 M | $ 3.41 | -3.67 % | $ 230 B | ||
|
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 316.2 | -4.28 % | $ 41.4 B | ||
|
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | ||
|
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | ||
|
argenx SE
ARGX
|
-861 M | $ 743.15 | -0.68 % | $ 25 B | ||
|
Завод ДИОД
DIOD
|
1.21 B | - | - | - | ||
|
Фармсинтез
LIFE
|
-3.54 B | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | ||
|
Aptorum Group Limited
APM
|
-72.4 M | $ 0.89 | - | $ 4.85 M | ||
|
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | ||
|
Teligent, Inc.
TLGT
|
-121 M | - | -13.85 % | $ 16.1 M | ||
|
Cerus Corporation
CERS
|
-1.08 B | $ 1.8 | -2.7 % | $ 343 M | ||
|
AbbVie
ABBV
|
-15.5 B | $ 202.28 | -2.11 % | $ 358 B | ||
|
Aquestive Therapeutics
AQST
|
-447 M | $ 4.04 | -1.28 % | $ 432 M | ||
|
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | ||
|
Viela Bio, Inc.
VIE
|
-427 M | - | - | $ 2.91 B | ||
|
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.63 | -2.69 % | $ 191 M | ||
|
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.32 | -2.06 % | $ 992 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-515 M | $ 8.12 | -1.22 % | $ 222 M | ||
|
Ardelyx
ARDX
|
-947 M | $ 5.8 | -2.93 % | $ 1.4 B |